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disability in humans. Currently, no effective treatments can
restore lost renal function after kidney damage in the
clinic. An increasing number of studies have provided evi-
dence that cell transplantation can lead to the repair of
damaged kidney tissue and functional recovery in preclin-
ical kidney models, including transplantation of bone
marrow-derived cells (BMDCs), mesenchymal stem cells
(MSCs), and embryonic stem (ES) cells.1 These cells have
been shown to differentiate into mesoderm lineages to
replace lost cells and partially reconstruct damaged kidney
circuitry. Several studies have shown that BMDCs can
engraft into kidneys, suggesting bone marrow (BM) is an
attractive somatic stem cell source for kidney cell turnover
and repair after injury. Although BM is a primary source of
hematopoietic stem cells and MSCs, the procurement of BM
is a highly invasive procedure, and the number and plas-
ticity of BM cells decline as individuals age. ES cells as well
as MSCs have attracted much attention because of their
unique biological behaviors and potential clinical usages.
However, the use of human embryos to derive cells is
associated with many legal and ethical issues. This has led
many researchers to investigate alternative sources of stem
cells.Conflicts of interest: The authors have no conflicts of interest
relevant to this article.
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ined to improve cell function and optimize cell-based
therapy. Yamanaka et al first described induced pluripo-
tent stem (iPS) cells that are reprogrammed from fibro-
blasts by ectopically expressing factors known to be highly
expressed in murine ES cells. iPS cells proliferate rapidly
while maintaining pluripotency, namely, the ability to
differentiate into various types of cells. Recent reports
have demonstrated the capacity of iPS cells to repair kid-
neys after injuries. For example, Lee et al2 showed that iPS
cell transplantation via the intrarenal arterial route effec-
tively reduces the expression of oxidative substances,
proinflammatory cytokines, and apoptotic factors in kidney
tissues injured by ischemia-reperfusion, and eventually
improves survival in rats. Furthermore, iPS cells trans-
planted into injured regions have been shown to survive
and express kidney cell markers. The capacity of iPS cells to
expand and differentiate into cells expressing renal lineage
or nephrogenic intermediate mesoderm markers is being
investigated extensively in vitro.3,4,5
It is currently believed that the regenerative effects of
iPS cells offer new prospects for regenerative medicine and
drug discovery for injured kidneys. iPS cells behave in a
manner similar to that of ES cells, having a high reproduc-
tion ability and pluripotency to differentiate into various
types of cells. Furthermore, iPS cells can be generated from
cells of any part of an adult patient, avoiding ethical
problems and immune rejection. iPS cells have not only
been shown to attenuate kidney injury in animal models but
have also been used as tools in vitro for studying disease
pathophysiology and inventing new therapeutic agents.3by Elsevier Taiwan LLC. This is an open access article under the
/4.0/).
594 W.-C. Shen et al.Many researchers believe that the renoprotective effects of
iPS cells are mediated by an increase of antiapoptotic, anti-
inflammatory, and antifibrogenic factors, as well as differ-
entiation into specific kidney cell types. However, the
mechanisms by which iPS cells exert their beneficial effects
remain controversial and more studies are required.
One study reports that iPS cells develop teratoma more
efficiently and faster than ES cells regardless of the site of
injection.6 It remains to be determined whether such path-
ological features can be directly attributed to alterations at
the genome level during reprogramming and prolonged pas-
sage in vitro. Recent analyses suggest that the pluripotent
and tumorigenic capacity of iPS cells may be governed by
different cell signaling pathways. It is now possible to repro-
grammouse andhuman somatic cells to a pluripotent state by
ectopic expression of the factors OCT4 and SOX2,without the
need for the oncogenes c-MYC or KLF4. This necessitates a
thorough molecular understanding of the iPS cells with
respect to their developmental potential and risk of ill
behavior if their derivatives were grafted into an individual.
The kidney is yet to substantially benefit from iPS cell
technology, although increasing attention has been paid to
the possible applications in kidney disease modeling.7
Future challenges will involve learning how to redifferen-
tiate iPS cells into the many cell types of the kidney,5
gaining insight into kidney disease pathophysiology using
disease-specific iPS cells,3 and innovating novel therapeutic
interventions.8
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